Unlock instant, AI-driven research and patent intelligence for your innovation.

Alphavirus replicon particle

一种甲病毒属、复制子的技术,应用在病毒、病毒肽、病毒/噬菌体等方向,能够解决缺少基因、基因疗法临床应用限制等问题

Pending Publication Date: 2020-10-02
VLP THERAPEUTICS LLC
View PDF17 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The clinical application of gene therapy remains limited due to the lack of suitable methods for the correct introduction of genes into cells, and as such, it is an area of ​​interest for many researchers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alphavirus replicon particle
  • Alphavirus replicon particle
  • Alphavirus replicon particle

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0189] Construction of VEEV Replicon Particles (VRP)

[0190] Schematic procedure such as figure 2 shown.

[0191] Establishment of VEEV replicon plasmid expressing luciferase

[0192] 1) Full-length VEEV TC83 nonstructural protein (nsp) 1, nsp2, nsp3 and nsp4 fragments were synthesized (ThermoFisher).

[0193] Similarly, the synthesis (IDT) of gblocks corresponding to the individual fragments of the replicon construct was as follows −

[0194] 2) VEEV gblock1 - ClaI-RSVp-5'UTR-nsp1 (bp1-470)-RsrII-ApaI-26Sp-sgRNA up to ATG of VEEV CA gene. This fragment has a 36 bp overlap with the pBR322 backbone plasmid at the 5' end. This is snippet #1.

[0195] 3) VEEV gblock2 - This fragment has a 64 bp overlap with VEEV gblock1 starting at the ApaI site until the ATG start codon. Next are the first 72 bases of Nano Luciferase ORF (Promega) and VEEV 3'UTR.

[0196] 4) Clone fragment #2 - VEEV gblock2, full-length VEEV 3' UTR and VEEV poly-A signal (A (n=55) ) were first assemble...

Embodiment 2

[0208] Determining the ability to package VEEV replicons into VEE viral replicon particles (VRPs)

[0209] Infection and luciferase assay

[0210] Schematic scheme such as Figure 8 shown.

[0211] 293T cells were seeded in complete DMEM in 96-well plates at a density of approximately 10,000 cells per well. Cells were infected with undiluted or 2-fold serial dilutions of harvested VRP at 37°C. 14 hours post infection (hpi), VRP was removed; cells were washed with PBS and fresh DMEM was added to the wells. Cells were further incubated and harvested for luciferase assay at 24, 48 and 72 hpi. Luciferase assays were performed by adding equal amounts of infected cells and the Nano-Glo Luciferase Assay System (Promega) to white bottom opaque 96-well plates (Costar). Luciferase activity was measured immediately using a Bio-Tek Synergy HTX microplate reader.

[0212] result

[0213] The result is as Figure 9 shown. Luciferase expression was confirmed in cells infected with V...

Embodiment 3

[0215] New VEEV replicon constructs

[0216] New VEEV TC83 replicon plasmid constructs were made by introducing a multiple cloning site (MCS) to enable the introduction of various "genes of interest". Schematic scheme such as Figure 10 shown. The construct is as Figure 11 and shown in SEQ ID NO: 6. exist Figure 11 In the construct of , the nucleotide encoding luciferase was introduced as the target gene. The promoter in the plasmid can be selected according to the cells to be infected.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is an alphavirus replicon particle (ARP), which comprises (i) alphavirus structural proteins comprising capsid and / or envelope, and (ii) an alphavirus replicon comprising a polynucleotide encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and at least one gene of interest wherein at least one of capsid, and E3 and E2 in the envelope comprise one or more amino acid alteration but E1 in the envelope comprises no amino acid alteration.

Description

technical field [0001] The present invention relates to alphavirus replicon particles useful as gene delivery systems. Background technique [0002] Gene therapy aims to introduce genetic material into cells to compensate for abnormal genes or to produce beneficial proteins. If a mutated gene causes an error or absence of an essential protein, gene therapy may be able to introduce a normal copy of the gene to restore the protein's function. [0003] Gene therapy is an emerging field of medicine and pharmacy due to its potential in treating chronic diseases such as cancer, viral infections, myocardial infarction, and genetic disorders. [0004] Genes that are inserted directly into cells usually don't work. Instead, a carrier called a vector is genetically engineered to deliver the gene. Certain viruses are commonly used as vectors because they can deliver new genes by infecting cells. The virus is modified so that it does not cause disease when used in humans. Certain t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/86C12N7/01
CPCA61K39/12C07K14/005C12N15/86C12N2770/36122C12N2770/36134C12N7/00C12N2770/36152C12N2770/36143A61K39/001162A61P35/00C07K16/2818A61K39/395C07K2317/76A61K2039/505Y02A50/30A61K2300/00A61K48/00C12N2770/36123
Inventor 赤畑涉上野隆司
Owner VLP THERAPEUTICS LLC